Cargando…
Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain Ligilactobacillus salivarius PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469334/ https://www.ncbi.nlm.nih.gov/pubmed/34576828 http://dx.doi.org/10.3390/microorganisms9091933 |
_version_ | 1784573904497410048 |
---|---|
author | Jiménez, Esther Manzano, Susana Schlembach, Dietmar Arciszewski, Krzysztof Martin, Rocio Ben Amor, Kaouther Roelofs, Mieke Knol, Jan Rodríguez, Juan Miguel Abou-Dakn, Michael |
author_facet | Jiménez, Esther Manzano, Susana Schlembach, Dietmar Arciszewski, Krzysztof Martin, Rocio Ben Amor, Kaouther Roelofs, Mieke Knol, Jan Rodríguez, Juan Miguel Abou-Dakn, Michael |
author_sort | Jiménez, Esther |
collection | PubMed |
description | Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain Ligilactobacillus salivarius PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-blind, placebo-controlled trial, 328 women were assigned to the probiotic or the placebo group. The intervention started from the 35th week of pregnancy until week 12 post-partum. The primary outcome was the incidence (hazard) rate of mastitis, defined as the presence of at least two of the following symptoms: breast pain, breast erythema, breast engorgement not relieved by breastfeeding, and temperature > 38 °C. The probability of being free of mastitis during the study was higher in the probiotic than in the placebo group (p = 0.022, Kaplan–Meier log rank test) with 9 mastitis cases (6%) vs. 20 mastitis cases (14%), respectively. The hazard ratio of the incidence of mastitis between both study groups was 0.41 (0.190–0.915; p = 0.029), indicating that women in the probiotic group were 58% less likely to experience mastitis. In conclusion, supplementation of L. salivarius PS2 during late pregnancy and early lactation was safe and effective in preventing mastitis, which is one of the main barriers for continuing breastfeeding. |
format | Online Article Text |
id | pubmed-8469334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84693342021-09-27 Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial Jiménez, Esther Manzano, Susana Schlembach, Dietmar Arciszewski, Krzysztof Martin, Rocio Ben Amor, Kaouther Roelofs, Mieke Knol, Jan Rodríguez, Juan Miguel Abou-Dakn, Michael Microorganisms Article Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain Ligilactobacillus salivarius PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-blind, placebo-controlled trial, 328 women were assigned to the probiotic or the placebo group. The intervention started from the 35th week of pregnancy until week 12 post-partum. The primary outcome was the incidence (hazard) rate of mastitis, defined as the presence of at least two of the following symptoms: breast pain, breast erythema, breast engorgement not relieved by breastfeeding, and temperature > 38 °C. The probability of being free of mastitis during the study was higher in the probiotic than in the placebo group (p = 0.022, Kaplan–Meier log rank test) with 9 mastitis cases (6%) vs. 20 mastitis cases (14%), respectively. The hazard ratio of the incidence of mastitis between both study groups was 0.41 (0.190–0.915; p = 0.029), indicating that women in the probiotic group were 58% less likely to experience mastitis. In conclusion, supplementation of L. salivarius PS2 during late pregnancy and early lactation was safe and effective in preventing mastitis, which is one of the main barriers for continuing breastfeeding. MDPI 2021-09-11 /pmc/articles/PMC8469334/ /pubmed/34576828 http://dx.doi.org/10.3390/microorganisms9091933 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jiménez, Esther Manzano, Susana Schlembach, Dietmar Arciszewski, Krzysztof Martin, Rocio Ben Amor, Kaouther Roelofs, Mieke Knol, Jan Rodríguez, Juan Miguel Abou-Dakn, Michael Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
title | Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
title_full | Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
title_fullStr | Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
title_full_unstemmed | Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
title_short | Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial |
title_sort | ligilactobacillus salivarius ps2 supplementation during pregnancy and lactation prevents mastitis: a randomised controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469334/ https://www.ncbi.nlm.nih.gov/pubmed/34576828 http://dx.doi.org/10.3390/microorganisms9091933 |
work_keys_str_mv | AT jimenezesther ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT manzanosusana ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT schlembachdietmar ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT arciszewskikrzysztof ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT martinrocio ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT benamorkaouther ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT roelofsmieke ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT knoljan ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT rodriguezjuanmiguel ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT aboudaknmichael ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial AT ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial |